Get ready for a thrilling journey as Eli Lilly and Company embarks on a new chapter of growth! The company is not only announcing two fresh faces on its Executive Committee but also expanding the roles of its senior leaders to accelerate innovation and access to life-changing medicines.
First up, meet Carole Ho, M.D., an industry veteran with over 20 years of experience in biopharmaceuticals. Ho will join Lilly as Executive Vice President and President of Lilly Neuroscience, bringing her expertise in neurology, rare diseases, and immunology to the table. Most recently, she served as Chief Medical Officer at Denali Therapeutics, where she crafted and led the company's clinical development strategy. With Ho on board, Lilly is poised to make significant strides in neuroscience.
And now, let's welcome Adrienne Brown, who has been promoted to Executive Vice President and President of Lilly Immunology. Brown, a seasoned leader with over 20 years at Lilly, has held various leadership roles across U.S. and Japan operations, business development, sales, marketing, and commercial strategy. She even led the successful U.S. launch of Mounjaro. Brown's expertise will undoubtedly drive Lilly's expansion plans in immunology.
But here's where it gets even more exciting! Daniel Skovronsky, M.D., Ph.D., is taking on an expanded role as Chief Scientific and Product Officer and President of Lilly Research Laboratories. He will oversee research and development, global launches, and product strategy for Cardiometabolic Health, Immunology, and Neuroscience. Skovronsky will continue to report directly to David A. Ricks, Lilly's Chair and CEO, and remain on the Executive Committee. New Executive Committee members Ho and Brown, along with Kenneth Custer, Ph.D., will all report to Skovronsky.
Additionally, Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, will also expand his role to include the corporate business development function under his leadership. Van Naarden will continue to report directly to Ricks and remain on the Executive Committee.
David A. Ricks, Lilly's Chair and CEO, shared his excitement about these changes, stating, "In recent years, Lilly has transformed our research engine, sped development, and launched breakthrough medicines while expanding production capacity and improving access to care and affordability. Looking ahead, we see an even greater opportunity to help people live better lives and grow our company's impact. To enable this exciting future, we're adding two exceptional leaders in Carole and Adrienne to drive our expansion plans in neuroscience and immunology, and we're expanding the scope of responsibilities for Dan and Jake. I'm thrilled to continue working with my colleagues to turn Lilly's long-term potential into reality."
Lilly, a medicine company with a rich history spanning nearly 150 years, is dedicated to turning science into healing. Their medicines have helped tens of millions of people worldwide, and they continue to push boundaries in biotechnology, chemistry, and genetic medicine. With a focus on diabetes care, obesity treatment, Alzheimer's disease, immune system disorders, and cancer transformation, Lilly is committed to solving some of the world's most pressing health challenges.
As Lilly embarks on this next wave of growth, they emphasize the importance of diversity in clinical trials and ensuring their medicines are accessible and affordable. To learn more about Lilly's journey and impact, visit their website at Lilly.com or follow them on social media platforms like Facebook, Instagram, and LinkedIn.
All trademarks and trade names mentioned in this press release are the property of their respective owners, and their use does not imply any relationship, endorsement, or sponsorship between Lilly and these companies.
This press release contains forward-looking statements, including about Lilly's leadership and strategic plans. However, there are no guarantees of achieved objectives or strategy execution as planned. For further discussion of risks and uncertainties, please refer to Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission.
Are you excited about Lilly's future and the potential impact of these leadership changes? Share your thoughts in the comments below! We'd love to hear your perspective on this exciting news.
